PTEN and prostate carcinoma: Specifically, metabolomic analyses of tumors from a Pten-deficient prostate cancer (PCa) mouse model, and of human PCa biopsies, revealed increases in dcSAM, N-acetyl-SPD and N-acetyl-SPM [78], and these changes were linked to increased levels of AMD1 protein but not mRNA.